Audio: Open label phase 2 multi-center study looking at Lasofoxifene (LAS) in combination with a Abemaciclib (Abema) for treating postmenopausal women with locally advanced or metastatic ER+ HER2 negative breast cancer with an ESR1 mutation..Read Full Transcript Here
Halle Moore, MD, Associate Professor, Department of Medicine, School of Medicine, Member, Population and Cancer Prevention Program, Case Comprehensive Cancer Center at Cleveland Clinic. In this video, she speaks about the ASCO 2022 Abstract – Â Open label phase 2, multicenter study of lasofoxifene (LAS) combined with abemaciclib (Abema) for treating pre-and postmenopausal women with locally advanced or metastatic ER+/HER2- breast cancer and an ESR1 mutation after progression on prior therapies and Operational metrics for the ELAINE II study combine a traditional approach with a Just-in-Time model.
Brief Overview:
This is an open-label, multicenter, single-arm safety study to assess the safety and tolerability of lasofoxifene and abemaciclib in pre- and postmenopausal women with locally advanced or metastatic ER+/HER2- breast cancer who have disease progression on first and/or second lines of hormonal treatment for metastatic disease and have an ESR1 mutation.